PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

24th Congress of EHA

June 13-16, 2019 Amsterdam

N. Poster

Poster title

Applicant name

Status


153-PF	MLL-AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER-PROMOTER INTERACTIONS	eva hortas	Received

158-PF	TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520	Matteo Marchesini	Received

162-PF	FREQUENCY AND PROGNOSTIC IMPACT OF ZEB2 H1038/Q1072 MUTATIONS IN CHILDHOOD B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA	Marketa Zaliova	Received

163-PF	TARGETING LYSOSOMES AS A POTENTIAL THERAPEUTIC APPROACH FOR T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	Antonia Mulet	Received

170-PF	ETV6/RUNX1 FUSION GENE ABROGATION DECREASE THE ONCOGENIC POTENCIAL OF TUMORS CELLS IN A PRECLINICAL MODEL OF ACUTE LYMPHOBLASTIC LEUKEMIA	Adrián Montaño	Received

174-PF	GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL	Sabina Chiaretti	Received

177-PF	NATION-WIDE PROSPECTIVE, REAL-TIME MONITORING OF PEGYLATED E.COLI AND ERWINIA ASPARAGINASE THERAPY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA IN BELGIUM	veerle Mondelaers	Received

179-PF	DIFFERENT IMPACT OF BCR BREAKPOINT ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FROM DIFFERENT GRAFT SOURCE FOR PHALL IN THE ERA OF TKI	Satoshi Nishiwaki	Received

182-PF	CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL)	Jose Maria Ribera Santasusana	Received

184-PF	EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY.	Akio Shigematsu	Received

188-PF	NGS COMBINED WITH ASO REAL-TIME PCR BASED MRD DETECTION ASSAY FOR PEDIATRIC ALL PATIENTS	Katerina Nicolaou	Received

189-PF	APPROPRIATE INTERVAL OF MONITORING FOR DETECTION OF MOLECULAR RELAPSE AFTER STOP OF TKI IN PHALLIN PH ALL CALCULATING BY MRD KINETICS	KOICHI MIYAMURA	Received

204-PF	TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT	BARBARA DEPRETER	Received

206-PF	DUAL TARGETING OF LYSOSOMES AND MITOCHONDRIA BY ANTIHISTAMINES TO ERADICATE LEUKEMIC CELLS	Josep Maria Cornet-Masana	Received

207-PF	TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN	Christian Augsberger	Received

210-PF	CLINICAL ASPECTS AND DIFFERENTIAL SPLICING IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SRSF2, U2AF1 AND SF3B1 MUTATIONS	Stefanos Bamopoulos	Received

211-PF	MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL	Reinaldo Dal Bello	Received

212-PF	NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS	Nicholas Short	Received

216-PF	ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL	Bruno Paiva	Received

221-PF	MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME	Esther Onecha	Received

224-PF	NOVEL ICMT INHIBITOR AS POTENTIAL TREATMENT OF RAS-DRIVEN ACUTE MYELOID LEUKEMIA	Miguel Gallardo	Received

226-PF	AUTOMATIC SEPARATION OF ABERRANT CELL CLUSTERS IN STANDARDIZED FLOW CYTOMETRY EXPERIMENTS PROVIDES A HIGHLY REPRODUCIBLE STRATEGY FOR MONITORING MINIMAL RESIDUAL DISEASE IN ACUTE MYELOBLASTIC LEUKEMIA	VANESA DIAZ	Received

228-PF	DIAGNOSTIC VALUE OF PU.1 LOCALIZATION IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1	Giulia Pianigiani	Received

229-PF	CLUSTER ANALYSIS IDENTIFIES A SPECIFIC IMMUNOPHENOTYPIC PROFILE ASSOCIATED WITH HIGH RISK OF PRIMARY INDUCTION FAILURE AND SHORTER OVERALL AND DISEASE-FREE SURVIVAL IN NPM1-MUTATED AML	piccini matteo	Received

235-PF	COMPREHENSIVE GENETIC TEST TO DETECT ALL GENE FUSIONS IN HEMATOLOGICAL MALIGNANCIES?	Eva van den Berg-de Ruiter	Received

243-PF	AN MLL-AF9 ZEBRAFISH LEUKAEMIA MODEL	Maryam Saberi	Received

250-PF	HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA	Pedro Aguilar-Garrido	Received

253-PF	SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS	Nicholas Howard	Received

255-PF	INCIDENCE AND RISK FACTORS FOR EARLY DEATH AMONG 2421 APL PATIENTS: THE PETHEMA REGISTRY EXPERIENCE	Marta Sobas	Received

257-PF	GEMTUZUMAB OZOGAMICIN COMBINED WITH CYTARABINE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN FIRST RELAPSE	Aude-Marie Fourmont	Received

258-PF	REAL-WORLD DATA ON DOSE-RELATED EFFECT OF ARSENIC TRIOXIDE IN THE RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA	Huaiyu Wang	Received

259-PF	THE COMBINATION OF BEMCENTINIB, A NOVEL, ORAL, SELECTIVE AXL-INHIBITOR AND LOW-DOSE CYTARABINE YIELDS DURABLE RESPONSES IN AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY	Zoe Roberts	Received

264-PF	TREATMENT INTENSIFICATION WITH FLAG-IDA MAY IMPROVE DISEASE CONTROL IN YOUNGER PATIENTS WITH SECONDARY AML WHICH MANIFESTS ITSELF WITH LONGER FOLLOW-UP: LONG-TERM ANALYSIS OF THE MRC AML15 TRIAL	Robert Hills	Received

266-PF	COMBINING FLOW CYTOMETRY-BASED LEUKEMIC CELL ENRICHMENT AND MUTATIONAL ANALYSIS FOR DETECTION OF RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA: A PILOT STUDY	Albert Woelfler	Received

267-PF	RISK ASSESSMENT OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH ACUTE LEUKEMIA AND CONCOMITANT ISCHEMIC HEART DISEASE	Tetiana Lymanets	Received

268-PF	DECIPHERING THE ABERRANT IMMUNE MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA DEVELOPMENT AND ITS ROLE IN CHEMOTHERAPY RESPONSE AND RELAPSE	Heng Mei	Received

270-PF	IS ACUTE MYELOBLASTIC LEUKEMIA IN CHILDREN UNDER TWO YEARS OF AGE A SPECIFIC ENTITY? A REPORT FROM THE FRENCH ELAM02 STUDY GROUP.	Sophie Blais	Received

271-PF	USING NEXT-GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS	Jonathan Canaani	Received

282-PF	THE EFFECT OF MODERN THERAPEUTICS IN ADULT ACUTE MYELOID LEUKEMIA (AML): POPULATION-BASED ANALYSIS OF LONG-TERM OUTCOMES FROM THE MANITOBA CANCER REGISTRY	Matthew Seftel	Received

283-PF	A RETROSPECTIVE STUDY OF MYELOID LEUKAEMIA IN CHILDREN WITH DOWN SYNDROME IN IRELAND	Gavin Dowling	Received

285-PF	ZELLA-101: PHASE 1 STUDY OF ALVOCIDIB FOLLOWED BY 73 INDUCTION IN NEWLY DIAGNOSED AML PATIENTS	Stephen Anthony	Received

286-PF	EARLY ADMISSION IN INTENSIVE CARE UNIT IS ASSOCIATED WITH LOWER MORBIDITY AND MORTALITY IN ACUTE MYELOID LEUKEMIA WITH HYPERLEUKOCYTOSIS: A RETROSPECTIVE ANALYSIS.	Nathan Mottal	Received

289-PF	SOCIOECONOMIC CONSEQUENCES AND OVERALL COSTS PER PATIENT WITH ACUTE MYELOID LEUKAEMIA (AML) IN SWEDEN A POPULATION-BASED STUDY USING MULTIPLE NATIONAL REGISTRIES	Simona Vertuani	Received

290-PF	INCIDENCE AND PROGNOSTIC IMPACT OF A BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM-LIKE PHENOTYPE IN AML PATIENTS.	Fabio Guolo	Received

295-PF	POPULATION-BASED STUDY ON DIFFERENT REGIMENS OF R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA IN THE NETHERLANDS SUPPORTS THE USE OF 6 CYCLES OF R-CHOP21	Djamila Issa	Received

301-PF	REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL	Yasuhiko Miyata	Received

302-PF	CENTRAL NERVOUS SYSTEM RELAPSE IN DIFFUSE LARGE B CELL LYMPHOMA: RISK FACTORS AND ROLE OF INTRATHECAL PROPHYLAXIS.	Eleonora Alma	Received

304-PF	Osteoporosis And Low-energy Fractures After Treatment For Lymphoma With Corticosteroid-containing Immunochemotherapy: A Danish Nationwide Cohort Study	Joachim Bch	Received

306-PF	A PHASE 2 STUDY OF OFATUMUMAB IN COMBINATION WITH HYPER-CVAD/MA IN PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA	Eva Hortas	Received

311-PF	ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY	Fatemeh Majidi	Received

315-PF	CLINICAL VALUE OF DIFFUSION-WEIGHTED WHOLE-BODY IMAGING WITH BACKGROUND BODY SIGNAL SUPPRESSION IN NEWLY DIAGNOSED LYMPHOMA PATIENTS	Eva Hortas	Received

316-PF	THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS	Oren Pasvolsky	Received

325-PF	REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTI-CENTER NATIONAL OBSERVATIONAL STUDY	shai shimony	Received

332-PF	THE EFFECT OF ANTITHROMBOTIC STEWARDSHIP ON THE EFFICACY AND SAFETY OF ANTITHROMBOTIC THERAPY DURING AND AFTER HOSPITALIZATION IN TWO DUTCH HOSPITALS	Albert Dreijer	Received

333-PF	RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS	Luca Pellegrini	Received

334-PF	EPIDURAL/SPINAL ANESTHESIA IN PREGNANT JEWISH ASHKENAZI WOMEN HETEROZYGOTES FOR FACTOR XI DEFICIENCY, A SINGLE CENTER PROSPECTIVE STUDY	Adi Shacham Abulafia	Received

337-PF	ALRN-6924, A DUAL INHIBITOR OF MDMX AND MDM2 THAT CAUSES MINIMAL THROMBOCYTOPENIA IN PATIENTS, DISRUPTS DIFFERENT STAGES OF THROMBOPOIESIS COMPARED TO MDM2-ONLY INHIBITION	Allen Annis	Received

338-PF	DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A	Wei Wang	Received

340-PF	PATIENTS WITH HIGHER BODY MASS INDEX TREATED WITH DIRECT / NON VITAMIN K DEPENDENT ANTICOAGULANTS (DOAC / NOAC) EXPERIENCE WORSE CLINICAL OUTCOMES	Marko Lucijanic	Received

344-PF	HIGH FREQUENCY ASXL1 MUTATIONS AND MULTIPLE SUBCLONAL PIGA MUTATIONS ARE OBSERVED IN CELLULAR AND CELL-FREE DNA IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	Georgie Ryland	Received

346-PF	Single cell transcriptome analysis reveals an essential role for gata2b in zebrafish hematopoietic lineage decisions	Emanuele Gioacchino	Received

357-PF	A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING	Claudia Perez	Received

359-PF	TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT	Luciana Cafforio	Received

365-PF	PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH BORDERLINE PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	Ilaria Del Giudice	Received

368-PF	DYSREGULATION OF BACH2 AND FOXP1 GENES IN T AND B CELLS IS MORE PRONOUNCED IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS WITH AN IMPACT ON SURVIVAL	DOMINIQUE BRON	Received

370-PF	SIGNAL-OMICS ANALYSIS OF THE IMPACT OF THERAPY ON BCR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA.	Adam Linley	Received

373-PF	IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING	Michel Ganard	Received

376-PF	DIFFERENTIAL GENOMIC AND TRANSCRIPTOMIC EVENTS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA	Jenny Klintman	Received

379-PF	PREVALENCE AND INCIDENCE OF CARDIOVASCULAR DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A NATION-WIDE POPULATION-BASED STUDY.	Karin Larsson	Received

380-PF	SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICOBIOLOGICAL FEATURES AND PROGNOSTIC VALUE	Michail Iskas	Received

382-PF	PROGNOSTIC MODELS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN EXEMPLAR SYSTEMATIC COCHRANE REVIEW AND META-ANALYSIS (PRELIMINARY RESULTS)	Nina Kreuzberger	Received

388-PF	HAT-PCR IS MORE SENSITIVE THAN FLOW FOR QUANTIFYING MRD IN CHRONIC LYMPHOCYTIC LEUKEMIA	Alexander Morley	Received

390-PF	FIRST-LINE TREATMENT WITH LENALIDOMIDE DOES IMPROVE OUTCOME IN ELDERLY/UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS	Julia Driessen	Received

391-PF	INFLUENCE OF ATORVASTATIN THERAPY ON GALECTIN-3, VE-CADHERIN, AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Borys Samura	Received

392-PF	MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE.	Andrea Corbingi	Received

393-PF	A RANDOMISED JOINT AUSTRALASIAN (ALLG) AND FRENCH (FILO) STUDY OF LENALIDOMIDE CONSOLIDATION IN PATIENTS WITH RESIDUAL CLL AFTER FRONT-LINE TREATMENT WITH FC/FCR (THE CLL6 TRIAL)	David Gottlieb	Received

402-PF	PECULIARITIES OF THE EXPRESSION OF KI-67 AND CD34 HEMOPOIETIC PRECURSOR CELLS IN PB AND BM OF CML PATIENTS WITH THE DIFFERENT RESPONSES TO IMATINIB AND NILOTINIB THERAPY	Tetiana Perekhrestenko	Received

410-PF	DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL	Dennis Kim	Received

419-PF	ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE ,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS).	LUIS FELIPE CASADO MONTERO	Received

420-PF	RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO-ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE-KINASE INHIBITORS FOR FIRST-LINE TREATMENT OF CML PTS (KIARO TRIAL)	Anna Sicuranza	Received

422-PF	THE LONG-TERM TREATMENT RESULTS ACCORDING TO THE MULTICENTER EUTOS ELN POPULATION-BASED STUDY (EUTOS-PBS) IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA	Olga Lazareva	Received

423-PF	SAFETY OF IMATINIB AND ITS GENERICS IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF POLISH IMATINIB GENERICS REGISTRY AFTER THREE YEARS OF OBSERVATION	Joanna W&261;c&322;aw	Received

427-PF	FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN-LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY	Leslie Todd	Received

432-PF	EPIDEMIOLOGICAL SHIFT OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) MUTATIONS IN NORTHERN ITALY DURING THE LAST 15 YEARS	Giovanna Graziadei	Received

433-PF	SOLUBLE MANNOSE RECEPTOR IS A POTENTIAL NEW BIOMARKER FOR PLASMA CELL DYSCRASIAS AND OTHER SKELETAL COMPLICATIONS IN GAUCHER DISEASE	Brendan Beaton	Received

434-PF	GLUCOPHOSPHATE ISOMERASE DEFICIENCY IDENTIFIED BY NEXT-GENERATION SEQUENCING	Sona Vora	Received

435-PF	A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EX-VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES	Josee Golay	Received

436-PF	GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY	Chiara F Magnani	Received

437-PF	PLATINUM TALEN-MEDIATED NON-VIRAL T CELL RECEPTOR GENE KNOCK-IN FACILITATES UNIVERSAL T CELL GENOME EDITING FOR MANUFACTURING OF THERAPEUTIC IMMUNE CELLS	Tatsuo Ichinohe	Received

443-PF	ADOPTIVE IMMUNOTHERAPY OF INVASIVE ASPERGILLOSIS BY T CELLS VACCINES AGAINST ASPERGILLOSIS IN MOUSE MODEL	haizhou xing	Received

444-PF	IDENTIFICATION OF T-CELL RECEPTORS FROM THE ALLOGENEIC-HLA REPERTOIRE SPECIFIC FOR MELANOMA-ASSOCIATED ANTIGENS	Marije de Rooij	Received

445-PF	INHIBITION OF ACUTE LYMPHOBLASTIC AND MYELOID LEUKEMIAS BY NOVEL CHIMERIC MOUSE-HUMAN MONOCLONAL ANTIBODIES AGAINST ANTIGEN PRAME	Andrey Misyurin	Received

453-PF	TRANSCRIPTOME-PROTEOME CORRELATION IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS	Fabienne Meier-Abt	Received

456-PF	BETA-CATENIN/TCF SIGNALING PATHWAY PROMOTES GRANULOCYTIC DIFFERENTIATION OF HEMATOPOIETIC PROGENITORS BY FACILITATING IL-1 RECEPTOR SIGNALING	Petr Danek	Received

459-PF	ANGELICA SINENSIS POLYSACCHARIDE MAINTAINS THE FUNCTION OF HEMATOPOIETIC STEM CELLS BY REGULATING THE TREG/TH17 RATIO AND THEREBY INDUCES ANTI-MITOCHONDRIAL APOPTOSIS IN APLASTIC ANEMIA	xing cui	Received

464-PF	DEFERASIROX DRIVES ROS-MEDIATED DIFFERENTIATION AND INDUCES INTERFERON-STIMULATED GENES EXPRESSION IN HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS AND IN LEUKEMIA CELLS	Tiziana Tataranni	Received

467-PF	NEW MOLECULES INSPIRED ON MICROBIOTA METABOLITES TARGETING ACUTE MYELOID LEUKEMIA CELLS	Sergio Algar	Received

469-PF	TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: UPDATED FOLLOW-UP EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY	Luidi Yang	Received

470-PF	FIVE-YEAR SURVIVAL AND DURABILITY RESULTS OF THE BEGEV REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA	Francesca Ricci	Received

471-PF	DEPRESSION AND ANXIETY IN HODGKIN LYMPHOMA SURVIVORS: A DANISH NATIONWIDE COHORT STUDY OF 896 PATIENTS	Andreas vlisen	Received

473-PF	PEDIATRIC HODGKIN LYMPHOMA: DISPARITIES IN SURVIVAL BY RACE	Karishma Khullar	Received

476-PF	SALVAGE OPTIONS FOR HD PATIENTS FAILING INITIAL ABVD TREATMENT	Oliver Karanfilski	Received

485-PF	PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB	Jorge Castillo	Received

489-PF	BR VS RCHOP AS INITIAL TREATMENT FOR ADVANCED STAGE FOLLICULAR LYMPHOMA: A MATCHED-PAIR ANALYSIS	PAOLO STRATI	Received

490-PF	PRESENCE OF BRAFV600E MUTATION IN CHILDHOOD LCH CORRELATES WITH MULTISYSTEM DISEASE AND A POOR SURVIVAL	PRATEEK BHATIA	Received

491-PF	RITUXIMAB is an effective therapy for Cold Agglutinin Disease but need to be used cautiously	Pierre Daufresne	Received

492-PF	RESPONSE AND SURVIVAL OUTCOMES OF WALDENSTROM MACROGLOBULINEMIA PATIENTS ON IBRUTINIB THERAPY ON AND OFF CLINICAL TRIAL	Jorge Castillo	Received

493-PF	TP53 STATUS IN MANTLE CELL LYMPHOMA (MCL) - A 10 YEAR SINGLE CENTER EXPERIENCE	Ezzat Elhassadi	Received

495-PF	WHIMSICAL (WALDENSTRMS MACROGLOBULINEMIA STUDY INVOLVING CART-WHEEL): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE DATA	Ibrahim Tohidi-Esfahani	Received

500-PF	A NEW FTL GENE MUTATION RESPONSIBLE FOR HYPOFERRITINEMIA WITHOUT IRON DEFICIENCY	Séverine Cunat	Received

501-PF	HOMOZYGOUS I281T MUTATION IN HJV CAUSING INDOLENT JUVENILE HEMOCHROMATOSIS WITH A MIDDLE TO LATE ONSET	Akiyoshi Takmai	Received

504-PF	LONG-TERM SEQUENTIAL DEFERIPRONE AND DEFERASIROX THERAPY INTRANSFUSION-DEPENDENT THALASSEMIA PATIENTS: A PROSPECTIVE CLINICAL TRIAL	Angela Vitrano	Received

507-PF	THE HEPCIDIN-ERYTHROFERRONE AXIS AND ITS RELATIONSHIP WITH ERYTHROPOIESIS IN DIFFERENT TYPES OF ANEMIA	Rafael Del Orbe Barreto	Received

510-PF	A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA	Maria Carmela Vegliante	Received

516-PF	ESTROGEN BETA RECEPTOR: A NEW TARGET FOR DIFFUSE LARGE B-CELL LYMPHOMA.	Myra Langendonk	Received

520-PF	C-REL NF-KAPPA B SUBUNIT ACTIVITY REFINES A DISTINCT GERMINAL CENTER DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUP WITH FAVORABLE OUTCOME	Jean Feuillard	Received

521-PF	CHOP TREATMENT ENHANCES DEPENDENCY ON BCL-2, MCL-1 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA	Mathilde de Jong	Received

526-PF	STRUCTURAL AND FUNCTIONAL VARIABILITY OF THE TUMOR B-CELL RECEPTOR INDICATES A ROLE FOR ENVIRONMENTAL INFLUENCES ON BEHAVIOR OF MANTLE CELL LYMPHOMAS	David Dutton	Received

527-PF	PROTEIN KINASE CK1 ALPHA INACTIVATION CAUSES MANTLE CELL LYMPHOMA GROWTH ARREST AND SYNERGISTICALLY ENHANCES IBRUTINIB CYTOTOXICITY	Francesco Piazza	Received

528-PF	INTEGRATING DETECTION OF COPY NEUTRAL CHROMOSOMAL LOSSES IN A CLINICAL SETTING IN LEUKEMIA AND LYMPHOMA BY MEANS OF ALLELIC IMBALANCE AND READ DEPTH RATIO COMPARISON	Marcus Hansen	Received

531-PF	TRANSFORMING ACTIVITIES OF THE NUP98-KMT2A FUSION GENE ASSOCIATED WITH MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA	James Fisher	Received

532-PF	INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.	Suguru Morimoto	Received

533-PF	MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS	Marta Martín Izquierdo	Received

534-PF	COPY NUMBER VARIATIONS AND UNIPARENTAL DISOMY PREDICT POOR SURVIVAL IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND ARE ASSOCIATED WITH MACROCYTOSIS	Stine Ulrik Mikkelsen	Received

535-PF	CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS.	GABRIELE TODISCO	Received

539-PF	MIR-223 IS SUPPRESSED IN EXOSOMES OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND MAY BE A MARKER OF RESIDUAL GRANULOCYTIC-MONOCYTIC DIFFERENTIATION	Bruno Benites	Received

543-PF	PROMOTER METHYLATION OF TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA	Naoki MORI	Received

545-PF	EASIX FOR PREDICTION OF SURVIVAL IN LOWER RISK MYELODYSPLASTIC SYNDROMES	Almuth Maria Anni Merz	Received

547-PF	FACTORS ASSOCIATED WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME (MDS). DATA FROM THE REGULAR CARE MDS-REGISTRY IN GERMANY	H.T. Steinmetz	Received

550-PF	AZACITIDINE (VIDAZA) IN PEDIATRIC PATIENTS WITH RELAPSED ADVANCED MDS: RESULTS OF A PHASE I/II STUDY BY THE ITCC CONSORTIUM AND THE EWOG-MDS GROUP: STUDY ITCC-015	Natasha van Eijkelenburg	Received

554-PF	A GENOME-WIDE CRISPR SCREEN IDENTIFIES TOP2B AS AN ACQUIRED DRUGGABLE VULNERABILITY IN THE CONTEXT OF IMID RESISTANCE	Matteo Costacurta	Received

561-PF	DUAL-TARGETING OF PROMOTER AND ENHANCER DRIVEN PROCESSES SUPPRESSES MYELOMA CELL GROWTH AND VIABILITY VIA PERTURBATION OF THE MYELOMA PROLIFERATIVE PROGRAM.	Mariateresa Fulciniti	Received

563-PF	MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)	Nouf Alrasheed	Received

565-PF	MMBMSCS INDUCE IMMUNOSENESCENT NAVE CD4 T-CELLS THROUGH THE NOVEL INTERCELLULAR COMMUNICATION TUNNELING NANOTUBES	Yadan Wang	Received

566-PF	INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY	Alejandra Ortiz-Ruiz	Received

572-PF	ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA	Takuto Tachita	Received

573-PF	SINGLE CELL RNA-SEQ REVEALED A RARE ITGA2 EXPRESSING CELL SUBPOPULATION WITH DISTINCT CANCER STEM CELL MARKER SIGNATURE IN MULTIPLE MYELOMA	Margaret Ng	Received

579-PF	TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA.	Paola Omedè	Received

582-PF	PARTICIPATION OF IMMUNE RESPONSE GENES POLYMORPHISM IN THE OCCURRENCE OF SOLID TUMORS IN PATIENTS WITH MULTIPLE MYELOMA	Elena Nazarova	Received

586-PF	SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY	Alessandra Larocca	Received

606-PF	ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA	Amani Erra	Received

607-PF	MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012-03).	Arthur Bobin	Received

611-PF	MULTIPLE DRUG COMBINATIONS FOR FIRST-LINE TREATMENT IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS	Vanessa Piechotta	Received

615-PF	IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY	MARTA GRANDE	Received

620-PF	COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL	Femke de Snoo	Received

621-PF	REAL WORLD EXPERIENCE IN THE MANAGEMENT OF WALDENSTRMS MACROGLOBULINAEMIA FROM ANALYSIS OF THE RORY MORRISON REGISTRY	Joshua Bomsztyk	Received

627-PF	SERUM CEREBLON LEVELS PREDICT FIVE- YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS.	Annita Ioanna Gkioka	Received

630-PF	MINIMAL RESIDUAL DISEASE MONITORING AND DEPTH OF RESPONSE IN MULTIPLE MYELOMA	Eva Hortas	Received

633-PF	PROGNOSTIC VALUE OF KIDNEY BIOPSY INTERSTITIAL FIBROSIS IN REVERSIBILITY OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY DUE TO MYELOMA CAST NEPHROPATHY	Evgeniya Kazarina	Received

634-PF	OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM)	Louise Ainley	Received

635-PF	SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS	Hiroki Kobayashi	Received

636-PF	NATURAL KILLER CELL ALLOREACTIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS	Catharina Van Elssen	Received

638-PF	Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma	Keonwoo Yi	Received

642-PF	REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS A SINGLE CENTRE EXPERIENCE	Amanda Jurgensen-Rauch	Received

650-PF	AGE DOES NOT CONFER DIFFERENT FEATURES AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED ACTIVE MULTIPLE MYELOMA YOUNGER THAN 66 YEARS OF AGE TREATED IN A RECENT PERIOD.	ELOISA RIVA	Received

656-PF	EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS	kristian boasman	Received

657-PF	USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES	Gonzalo Carreno	Received

659-PF	MYELOMONOCYTIC SKEWING IN VITRO DISCRIMINATES SUBGROUPS OF PATIENTS WITH MYELOFIBROSIS WITH A DIFFERENT PHENOTYPE, A DIFFERENT GENOTYPE AND DIFFERENT PROGNOSIS	Temeida Graf	Received

660-PF	TRANSCRIPTIONAL PROFILES OF PRIMARY CULTURES OF ERYTHROID AND MEGAKARYOCYTIC CELLS IN ESSENTIAL THROMBOCYTHEMIA UNCOVER A HIGH DEGREE OF GENE DEREGULATION IN THE MEGAKARYOCYTIC LINEAGE.	Petros Papadopoulos	Received

661-PF	MOLECULAR PROFILING REVEALS HIGHLY DEREGULATED INSULIN GROWTH FACTOR BINDING PROTEINS IN PATIENTS WITH MYELOFIBROSIS AND RELATED NEOPLASMS	Vibe Skov	Received

664-PF	46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS	Gonzalo Carreno	Received

665-PF	SERUM FERRITIN LEVELS ARE INCREASED IN IDIOPATHIC ERYTHROCYTOSIS BUT REDUCED IN POLYCYTHEMIA VERA	Giacomo Biagetti	Received

669-PF	RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS	Chiara Cavalloni	Received

670-PF	MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA	Álvaro Díaz	Received

673-PF	PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)	PRITHVIRAJ BOSE	Received

674-PF	OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS	Francesca Palandri	Received

675-PF	JAK2V617F AND MPL MUTATIONS ARE ASSOCIATED WITH WORSENED SYMPTOM BURDEN THAN CALR IN THE MYELOPROLIFERATIVE NEOPLASMS: FINDINGS FROM THE MYMPN PATIENT REGISTRY	Robyn Scherber	Received

676-PF	BODY MASS INDEX AND TOTAL SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASMS DISCOVERY OF A U-SHAPED ASSOCIATION	Robyn Scherber	Received

682-PF	MULTICENTER RETROSPECTIVE STUDY EVALUATING FIBROSIS RISK IN PATIENTS WITH ET DEPENDING ON THE TREATMENT SCENARIO	Marta Sobas	Received

683-PF	ARTERIAL THROMBOSIS IN YOUNG PV PATIENTS	Giulia Bogoni	Received

684-PF	ANAGRELIDE MODULATES PROPLATELET FORMATION RESULTING IN DECREASED NUMBER AND INCREASED SIZE OF PLATELETS	Naohiro Miyashita	Received

686-PF	HEALTHCARE RESOURCE IMPLICATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS	Ximena Cabrera Castellano	Received

687-PF	RISK OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ACCORDING TO THE JAK2 V617F ALLELE BURDEN	Sung Hwa Bae	Received

689-PF	SAFETY AND EFFICACY OF ROMIPLOSTIM IN OVER 200 CHILDREN WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN AN INTEGRATED DATABASE OF 5 CLINICAL TRIALS	Jonathan Latham	Received

695-PF	ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP	Elisa Lucchini	Received

703-PF	LONG-TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM	Leslie Todd	Received

707-PF	INCIDENCE AND OUTCOMES OF REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN; A SINGLE INSTITUTION EXPERIENCE	Masataka Ito	Received

716-PF	CLINICAL IMPACT OF PROGNOSTIC NUTRITIONAL INDEX IN DIFFUSE LARGE B CELL LYMPHOMA	Gyeong-Won Lee	Received

717-PF	QUALITY OF LIFE (QOL), PERSPECTIVES ON TREATMENT AND IMPORTANT OUTCOMES FOR MULTIPLE MYELOMA (MM) PATIENTS AND THEIR CARERS: A MIXED METHODS EVIDENCE SYNTHESIS	Keith Stubbs	Received

718-PF	THE ECONOMIC AND HUMANISTIC BURDEN OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PEDIATRIC PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR)	Anna Forsythe	Received

727-PF	DOES QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS DIFFER BETWEEN NATIONALITIES? A EUROPEAN MULTINATIONAL STUDY	Ayesha Sajjad	Received

730-PF	CHRONIC RENAL FAILURE IN CHILDHOOD CANCER: AN INSIGHT FROM KIDS INPATIENT DATABASE	Eman Elsabbagh	Received

732-PF	AN INDEPENDENT OBSERVATIONAL STUDY OF REAL LIFE COSTS OF CARE TO MYELOMA PATIENTS IN THE ERA OF NOVEL THERAPIES	Jane Thompson	Received

742-PF	CEREBRAL OXYGEN METABOLISM MEASUREMENTS WITH MRI IN ADULTS WITH SICKLE CELL DISEASE	Lena Vaclavu	Received

743-PF	PENICILLIN PROPHYLAXIS AND PNEUMOCOCCAL VACCINE USE IN ADULT SICKLE CELL PATIENTS: A RETROSPECTIVE ANALYSIS OF CLINICAL PRACTICE AND OUTCOMES IN OXFORD, UK	Ayesha Ejaz	Received

745-PF	HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANT FOR POEMS SYNDROME: EFFECTIVE, BUT HOW TO OPTIMISE?	Oliver Tomkins	Received

753-PF	IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOID NEOPLASM	JUN YEB NAM	Received

756-PF	DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION	Kaori Uchino	Received

757-PF	REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE.	Nancy Rodriguez	Received

759-PF	ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON.	Andrea Corbingi	Received

763-PF	STEM CELL TRANSPLANTATION FOR MANTLE-CELL LYMPHOMA - A SINGLE CENTRE EXPERIENCE (2010-2018)	Telma Nascimento	Received

766-PF	T CELL EXHAUSTION PROFILE (CD4/CD28/PER/GRA CD8/CD28/PER/GRA) IN STEMCELL TRANSPLANTATION, CMV RE ACTIVATIONS AND RESPIRATORY VIRUS INFECTION.CELLULAR DYNAMICS IN THE FIRST 100 DAYS POST SCT	Miguel Villanueva	Received

770-PF	OUTCOMES FOR MELPHALAN-VELCADE BASED AUTOGRAFT IN HIGH RISK MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTRE EXPERIENCE	David Routledge	Received

775-PF	MONOSOMY 7 ALONE OR WITH OTHER CHROMOSOMAL ABNORMALITIES SIGNIFICANTLY AFFECT SURVIVAL OF SECONDARY AML PATIENTS TREATED WITH ALLOGENEIC- SCT	Mona Hassanein	Received

787-PF	THE EFFICACY OF ALENDRONATE FOR THE TREATMENT OF THALASSEMIA-ASSOCIATED OSTEOPOROSIS: A RANDOMIZED CONTROLLED TRIAL	Pokpong Piriyakhuntorn	Received

788-PF	DATA FROM THE FRENCH REGISTRY FOR BETA-THALASSEMIA PATIENTS	Badens Catherine	Received

789-PF	8-YEARS OVERALL AND EVENT FREE SURVIVAL IS SUBOPTIMAL IN A LARGE GROUP OF TRANSFUSION-DEPENDENT THALASSEMIC PATIENTS	antonis kattamis	Received

791-PF	IMPAIRMENT OF GLUTATHIONE SYSTEM AND LIPID PEROXIDATION IN PATIENTS WITH HB H DISEASE	ANTONIS KATTAMIS	Received

795-PF	EXPLORING THE REAL-LIFE CLINICAL VALUE OF LOW DOSE DIRECT ANTICOAGULANTS FOR SECONDARY PREVENTION OF THROMBOEMBOLISM	CHARALAMPOS KARTSIOS	Received

802-PF	ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L	Sergio Siragusa	Received

803-PF	VON WILLEBRAND FACTOR DELAYS LIVER REPAIR AFTER ACETAMINOPHEN-INDUCED ACUTE LIVER INJURY IN MICE.	Dafna Groeneveld	Received

813-PF	PROFILE OF BLOOD DONORS WITH SEROLOGIC TESTS REACTIVE IN HOSPITAL METROPOLITANO IN QUITO- ECUADOR FROM JANUARY 2016 TO DECEMBER 2018.	johanna rojas	Received

817-PF	INTENSIVE PLAN OF THERAPEUTIC PLASMA EXCHANGE IN PATIENT WITH EXTREME HYPERTRLIGLYCERIDEMIA DUE TO L-ASPARAGINASE IN THE CONTEXT OF SMILE PROTOCOL IN T/NK NASAL LYMPHOMA TREATMENT	Eduardo Sobejano	Received

914-PS	CONDITIONAL MEF2C EXPRESSION IN THE MOUSE THYMUS DRIVES DEVELOPMENT OF T/B-BIPHENOTYPIC LYMPHOID LEUKEMIA/LYMPHOMA	Kirsten Canté-Barrett	Received

918-PS	CIRCRNA DEREGULATION IN B-CELL PEDIATRIC ACUTE LEUKEMIA: THE MLL RECOMBINOME AND BEYOND	Stefania Bortoluzzi	Received

919-PS	ROLE OF CHOROID PLEXUS STROMA IN TUMOUR CHEMORESISTANCE: A SANCTUARY FOR LEUKAEMIA CELLS IN THE CENTRAL NERVOUS SYSTEM	Lidia Martínez	Received

921-PS	INACTIVATION OF SH2B3 THROUGH CN-LOH 12Q IS UNIQUELY ASSOCIATED WITH B-CELL PRECURSOR ALL WITH IAMP21 OR OTHER CHROMOSOME 21 GAIN.	Paul Sinclair	Received

933-PS	DISCOVERING PATHWAYS INVOLVED IN RESISTANCE TO INDUCTION THERAPY IN T-ALL TO TREAT REFRACTORY AND RELAPSED DISEASE	Melanie Beckett	Received

935-PS	APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Sabina Chiaretti	Received

937-PS	RANDOMIZED PHASE III HOVON-100 STUDY OF CLOFARABINE COMBINED WITH STANDARD TREATMENT IN ADULT PATIENTS WITH NEWLY DIAGNOSED ALL	Anita Rijneveld	Received

938-PS	INTENSIVE PAEDIATRIC THERAPY IS AS DELIVERABLE IN ADOLESCENTS AND YOUNG ADULTS AS CHILDREN WITH ALL - PRELIMINARY RESULTS OF THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA GROUP (ALLG) ALL06 STUDY	Matthew Greenwood	Received

941-PS	ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT IMPROVES LONG-TERM OUTCOME OF B-ALL PATIENTS WITH HIGH LEUKEMIA BURDEN OR POOR PROGNOSTIC MARKERS	Heng Mei	Received

942-PS	CD19 MUTATION FREQUENCY AFTER BLINATUMOMAB TREATMENT IS LOWER THAN AFTER CAR T-CELLS TREATMENT	Michaela Kotrova	Received

943-PS	SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE	Marie Emilie Dourthe	Received

952-PS	NELARABINE AS SALVAGE THERAPY FOR PEDIATRIC PATIENTS WITH RELAPSED T-ALL	luciana vinti	Received

956-PS	A MULTICENTER, RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BUSULFAN/FLUDARABINE CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA	SEUNG SHIN LEE	Received

957-PS	Initial safety and efficacy of larotrectinib in patients with B lymphoblastic leukaemia:data from an expanded access programme	Annabel Ola	Received

958-PS	IMPROVING THE SAFETY OF CAR-T CELL THERAPY BY CONTROLLING CRS-RELATED COAGULOPATHY	Heng Mei	Received

963-PS	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: DOES MINIMAL RESIDUAL DISEASE BEFORE TRANSPLANTATION MATTER FOR LONG TERM OUTCOME?	Irati Ormazabal Velez	Received

970-PS	ACUTE MYELOID LEUKEMIA CELLS ARE DEPENDENT ON S100A4 FOR GROWTH AND SURVIVAL	Bader Alanazi	Received

982-PS	THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA	Dagmar Stoiber	Received

984-PS	CANNABINOIDS EXERT A POTENT ANTI-LEUKEMIC EFFECT AFFECTING SIGNALING PATHWAYS INVOLVED IN TUMOR CELL METABOLISM.	Mayte Medrano	Received

991-PS	CA-4948, AN IRAK4/FLT3 INHIBITOR, SHOWS ANTILEUKEMIC ACTIVITY IN MOUSE MODELS OF FLT3 WILD-TYPE AND FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML)	Robert Booher	Received

992-PS	MSI2 REGULATES BACH1/BRIP1 THUS AFFECTING THE OXIDATIVE STRESS RESPONSE	Jessica Hoell	Received

995-PS	IMPACT OF DNMT3A MUTATIONAL STATUS IN MOLECULAR MEASURABLE RESIDUAL DISEASE CLEARANCE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1	Guadalupe Oñate	Received

996-PS	TCF4 IS IMPORTANT FOR MUTANT RUNX1-MEDIATED CELL IMMORTALIZATION AND PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA	Florentien in t Hout	Received

1002-PS	RHOE, CXCL12 AND CXCR3 MAY IDENTIFY COMPLETE RESPONSES IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH TIPIFARNIB	Antonio Gualberto	Received

1006-PS	INHIBITORS OF HOXA9 LEUKEMOGENIC TRANSCRIPTION FACTOR ARE EFFICIENT ON HUMAN AML CELL MODELS BUT NOT ON NORMAL HUMAN BONE MARROW CD34 HEMATOPOIETIC CELLS	Marie-Helene David-Cordonnier	Received

1008-PS	A NEW NEXT-GENERATION SEQUENCING STRATEGY FOR THE SIMULTANEOUS DETECTION OF GENE MUTATIONS AND COPY NUMBER VARIATIONS IN MYELOID MALIGNANCIES	M. Isabel Prieto-Conde	Received

1016-PS	COMPARATIVE ANALYSES OF LEUKEMIC BLAST PHENOTYPE AND MUTANT/WT EXPRESSION RATIO IN FLT3-ITD ACUTE MYELOID LEUKEMIAS	Dan-Sebastian Soare	Received

1017-PS	MICRO RNA SIGNATURE OF ONCOGENIC MUSASHI RNA BINDING PROTEINS MSI1 AND MSI2	Sujitha Duggimpudi	Received

1028-PS	ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY	Harry Iland	Received

1031-PS	DECITABINE VERSUS INTENSIVE CHEMOTHERAPY IN ELDERLY UNTREATED ACUTE MYELOID LEUKEMIA	Adolfo de la Fuente	Received

1032-PS	SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50-75 YEARS A SWEDISH POPULATION-BASED STUDY	Gunnar Juliusson	Received

1034-PS	PHASE I DOSE ESCALATION CLINICAL TRIAL OF H3B-8800, A SPLICING MODULATOR, IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES	Huilan Yao	Received

1037-PS	FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS	Iphigenia Koumenis	Received

1040-PS	DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS	Jing Wamg	Received

1045-PS	INDIRECT NUMBER NEEDED TO TREAT: COMPARATIVE EFFECTIVENESS OF GLASDEGIB LOW-DOSE CYTARABINE VS AZACITIDINE OR DECITABINE IN ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY	Anna Forsythe	Received

1046-PS	FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA.	Pierre Peterlin	Received

1047-PS	EFFICACY AND SAFETY EVALUATION OF DIFFERENT DOSES OF ANTHRACYCLINES IN THE INDUCTION THERAPY FOR NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA	Xiaohui Hu	Received

1050-PS	MARKER CHROMOSOME IS A STRONG POOR PROGNOSIS FACTOR AFTER ALLOGENEIC HSCT FOR AML PATIENTS	Kyoko Fuse	Received

1054-PS	INTENSIFIED CONDITIONING WITH FLUDARABINE/MELPHALAN PLUS TOTAL BODY IRRADIATION VERSUS FLUDARABINE/MELPHALAN ALONE FOR ACUTE MYELOID LEUKEMIA	Sarah Lindner	Received

1056-PS	ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG-TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION	GHULAM REHMAN MOHYUDDIN	Received

1057-PS	INDUCTION WITH FLUGA SCHEME AND MAINTENANCE WITH DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OF 65 YEARS AND OLDER	Sofía Costa	Received

1071-PS	PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES.	Shannon Matheny	Received

1074-PS	SANDOZ RITUXIMAB FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM SAFETY RESULTS OF THE PROSPECTIVE NON-INTERVENTIONAL, OBSERVATIONAL, MULTICENTER, OPEN-LABEL REFLECT STUDY	Jess Fox	Received

1077-PS	EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP	Kitsada Wudhikarn	Received

1084-PS	AUTOLOGOUS STEM CELL TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA: SIMILAR OUTCOMES AFTER BEAM AND FEAM CONDITIONING REGIMENS	Bruno Loureiro	Received

1096-PS	INTERIM UPDATE FROM A MULTI-CENTER STUDY OF PRALATREXATE IN ASIAN PATIENTS WITH RELAPSED OR REFRACTORY(R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL)	Bor-Sheng Ko	Received

1098-PS	ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION	Julian Freue	Received

1104-PS	EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION	Elena Egorova	Received

1114-PS	PATIENTS WITH GAUCHER DISEASE SHOW AN IMMUNE-DYSREGULATION PATTERN SECONDARY TO A DEFECT OF APOPTOSIS	Maurizio Miano	Received

1119-PS	PNH CLONE SIZE BY FLOW CYTOMETRY AND ITS CORRELATION TO PIG GENE MUTATION	Dajeong Jeong	Received

1120-PS	IRON MOBILIZATION IN A REAL LIFE COHORT OF APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG	Francesca Cavallaro	Received

1121-PS	ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA	Jennifer Tjon	Received

1128-PS	FUNGI INFECTION VERSUS IBRUTINIB TREATMENT: ROLE OF NURSE-LIKE CELLS DURING ASPERGILLUS FUMIGATUS INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS	Stefania Fiorcari	Received

1130-PS	STEM CELL FACTOR IS IMPLICATED IN MICROENVIRONMENTAL INTERACTIONS AND CELLULAR DYNAMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA	Stavroula Ntoufa	Received

1132-PS	INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Jennifer Brown	Received

1138-PS	TUMOR MUTATIONAL BURDEN ASSESSED BY TARGETED HIGH THROUGHPUT SEQUENCING PREDICTS TREATMENT FREE SURVIVAL IN CLL: RESULTS FROM A BICENTER STUDY	Jean Feuillard	Received

1141-PS	PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON-109 STUDY	Fatemeh Saberi Hosnijeh	Received

1152-PS	THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE	Luca Laurenti	Received

1153-PS	IMPACT OF COMORBIDITIES ON OUTCOMES OF THERAPY WITH IDELALISIB (IDELA), A PHOSPHOINOTISIDE-3 KINASE-DELTA INHIBITOR, IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Max Gordon	Received

1155-PS	A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Alexey Danilov	Received

1171-PS	TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB	Natalia Estrada	Received

1172-PS	DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME	Gioia Colafigli	Received

1175-PS	DETECTING BCR-ABL AND SCORING MR: RESULTS FROM A CE-IVD KIT RUN ON NON-IVD PCR INSTRUMENTS: A COMPARISON WITH DATA FROM A EUTOS VALIDATED LAB.	Jesper Petersen	Received

1177-PS	PROGNOSTIC FACTORS FOR MOLECULAR RELAPSE-FREE SURVIVAL AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA BASED ON RUSSIAN MULTICENTER PROSPECTIVE TRIAL (RU-SKI)	Oleg Shukhov	Received

1179-PS	TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS HARBOURING ATYPICAL BCR-ABL1 TRANSCRIPTS	MATTEO DRAGANI	Received

1180-PS	FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP)	Kiran Naqvi	Received

1184-PS	ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE	Asif Iqbal	Received

1193-PS	CHARACTERISTICS AND OUTCOMES OF THE TREATMENT PATIENTS WITH T315I MUTATION CML	Julia Vlasova	Received

1196-PS	INNOVATIVE DIAGNOSTIC APPROACH FOR RARE ANEMIA	Valeria Rizzuto	Received

1197-PS	ASSESSING THE EMA BINDING TEST AND OSMOTIC GRADIENT EKTACYTOMETRY IN THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS DEFINED BY THE PRESENCE OF UNDERLYING DIAGNOSTIC MUTATIONS	Andreas Glenthoej	Received

1203-PS	HEREDITARY SPHEROCYTOSIS: SCREENING AND DIAGNOSTIC APPROACH IN A BELGIAN LABORATORY	Edith Sepulchre	Received

1204-PS	SEVERE HEREDITARY HAEMOLYTIC ANAEMIA DUE TO THREE NOVEL SPTA1 MUTATIONS IN TWO COMPOUND HETEROZYGOUS UNRELATED PATIENTS.	Juan-Luis Vives-Corrons	Received

1209-PS	NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS.	Elena Maroto Martin	Received

1214-PS	INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19 RELAPSED / REFRACTORY MALIGNANCIES	Valentín Ortiz-Maldonado	Received

1215-PS	SAFETY AND TOLERABILITY OF ALLOGENEIC, OFF-THE SHELF PLACENTAL NATURAL KILLER CELLS (PNK 007) IN PHASE 1 MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA STUDIES (NCT02955550 AND NCT02781467)	Sharmila Koppisetti	Received

1219-PS	CAUSES OF NON ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL	Jérme PAILLASSA	Received

1222-PS	IL-6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR-T CELL THERAPY	Heng Mei	Received

1224-PS	DOWNREGULATION OF ENDOTHELIAL GENE MYCT1 IN HUMAN HSCS DURING EX VIVO CULTURE COMPROMISES THEIR FUNCTION	Julia Aguade-Gorgorio	Received

1228-PS	SF3B1 KNOCKDOWN AT EARLY ERYTHROPOIESIS INDUCED CELL APOPTOSIS BY USING A TET-ON LENTIVIRAL VECTOR	Yumin Huang	Received

1237-PS	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI	Rita Mazza	Received

1245-PS	NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: LONG TERM RESULTS OF MULTI-CENTER EXPERIENCE IN TURKEY	Burhan Ferhanoglu	Received

1248-PS	COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL	Daniele Grimaldi	Received

1254-PS	CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY	Jiajia Liu	Received

1255-PS	EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY	Rory McCulloch	Received

1258-PS	CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS	CHRISTINA KALPADAKIS	Received

1259-PS	LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA	Michinori Ogura	Received

1266-PS	CLINICAL ASPECTS, MORPHOLOGICAL ANALYSIS AND IMMUNOHISTOCHEMICAL CHARACTERISTICS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN DUODENUM BIOPSY: CASES WITH RESTRICT DISEASE VERSUS ADVANCED PRESENTATION.	Guilherme Brasil Duffles Amarante	Received

1269-PS	AUTOIMMUNE NEUTROPENIA OF INFANCY- UNEXPECTED PREVALENCE OF PSEUDOMONAS SKIN INFECTIONS	Joanne Yacobovich	Received

1270-PS	HIGH INCIDENCE OF CYTOMEGALOVIRUS (CMV) REACTIVATION IN HEMATOLOGICAL PATIENTS TREATED WITH BENDAMUSTINE BASED CHEMOTERAPY REGIMENS	luca pezzullo	Received

1274-PS	EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION INADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: ARETROSPECTIVE MONOCENTER STUDY	Francesca Bettelli	Received

1276-PS	EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS.	GABRIELE FACCHIN	Received

1284-PS	GLOBAL GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF MUCORMYCOSIS: AN INITIATIVE OF THE ECMM IN COOPERATION WITH THE MSG ERC	Kerstin Albus	Received

1289-PS	THE ATYPICAL LYMPHOCYTE COUNT: A NOVEL PREDICTIVE FACTOR FOR SEVERE DENGUE INFECTION	Visula Abeysuriya	Received

1291-PS	THE DEVELOPMENT OF IRON OVERLOAD SYNDROME IN PATIENTS WITH LOW-/INTERMEDIATE RISK MYELODYSPLASTIC SYNDROME	Tatiana Babaeva	Received

1292-PS	LINK BETWEEN IRON AND TRYPTOPHAN METABOLISM OBSERVED IN INDIVIDUALS WITH IRON DEFICIENCY AND ANEMIA	Dietmar Enko	Received

1300-PS	A NURSE LED IRON INFUSION CLINIC IMPROVES PATIENT SAFETY AND REDUCES HEALTH CARE COSTS	Laurie Newman	Received

1307-PS	USE OF T CELL-SPECIFIC RNA IN SITU HYBRIDISATION AS A NOVEL TEST TO DISTINGUISH MALIGNANT (LYMPHOMATOUS) AND BENIGN (INFLAMMATORY) T CELL INFILTRATES	Elizabeth Soilleux	Received

1315-PS	CHANGES IN THE SECRETOME COMPOSITION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITHOUT BONE MARROW INVOLVEMENT	Nataliya Petinati	Received

1317-PS	VITAMIN D3 INHIBITS GROWTH OF HODGKIN CELL LINES AND IMPROVES SENSITIVITY TO CHEMOTHERAPY AT PHYSIOLOGICAL DOSES IN VITRO AND IN VIVO.	Melita Cirillo	Received

1319-PS	MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19 SELECTED AND UNSELECTED SAMPLES	Daniela Drandi	Received

1321-PS	INHIBITION OF NOTCH SIGNALING RESTORES SENSITIVITY TO IMMUNOCHEMOTHERAPY IN AN IN VITRO MODEL OF ACQUIRED RESISTANCE TO R-CHOP	Giovanni Di Pinto	Received

1323-PS	HIGH SERUM LEVELS OF IL-2R, IL-6, AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA	Pablo MOZAS	Received

1325-PS	IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA	Yue Wei	Received

1327-PS	RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BM OF PATIENTS WITH MDS AND CMML	Veronika Dill	Received

1330-PS	VARIABILITY IN THE EXTENT OF DEL(5Q) AND ITS CLINICAL IMPLICATION IN MYELODYSPLASTIC SYNDROMES (MDS).	Zuzana Zemanova	Received

1331-PS	MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL	Temeida Graf	Received

1332-PS	RIGOSERTIB MODULATES HEMATOPOIESIS GENE SIGNALING PATHWAYS ALONE OR IN SEQUENCED COMBINATION WITH AZACTIDINE ON MDS CELLS IN VITRO.	Lewis R Silverman	Received

1333-PS	OVEREXPRESSION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE1 CAUSES STAT5 DEPHOSPHORYLATION, RESULTING IN SUPPRESSION OF CELL GROWTH SIGNAL IN K562 HUMAN LEUKEMIA CELLS	MASAYUKI SHISEKI	Received

1339-PS	UNSUPERVISED HIERARCHICAL CLUSTERING OF PRE-TREATMENT IMMUNOPHENOTYPIC FEATURES IDENTIFIES MDS PATIENTS AT HIGH RISK OF DISEASE PROGRESSION AFTER ALLOGENEIC TRANSPLANTATION	Madlen Jentzsch	Received

1341-PS	CLINICAL SIGNIFICANCE OF KIR GENOTYPE IN JAPANESE PATIENTS WITH MYELODYSPLASTIC SYNDROME	Norina Tanaka	Received

1342-PS	PREDICTING SURVIVAL AND TRANSFORMATION IN YOUNG AND MIDDLE-AGED PATIENTS WITH MYELODYSPLASTIC SYNDROME	Natalia Klimkovich	Received

1345-PS	CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION	Martina Manzoni	Received

1350-PS	STRONG PRE-CLINICAL RATIONAL FOR THE USE OF MCL1/BCL2 BH3 MIMETIC COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 MIMETIC ALONE	Carolane Seiller	Received

1351-PS	CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL.	Ana Jimenez Ubieto	Received

1354-PS	MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION	Saeko Ota	Received

1360-PS	LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS	Elisa Taiana	Received

1366-PS	TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANIZED BONE-ORGAN AS A PLATFORM FOR PRECLINICAL MULTIPLE MYELOMA RESEARCH	Alvaro Sanchez	Received

1367-PS	COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN	Takashi Kanamori	Received

1368-PS	IGH AND IGK REARRANGEMENT AND IGH SOMATIC HYPERMUTATION ANALYSIS USING NEXT-GENERATION SEQUENCING FOR THE DETECTION OF CLONALITY IN HIGH-RISK KOREAN MULTIPLE MYELOMA PATIENTS	Young Kyung Lee	Received

1371-PS	ELOTUZUMAB IN COMBINATION WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 2 MMRC TRIAL	Donna Stefanoni	Received

1383-PS	A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16)	Anna Kalff	Received

1386-PS	CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA	Frits van Rhee	Received

1397-PS	OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA	Brett Grieb	Received

1398-PS	RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT	Julio Davila	Received

1402-PS	OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM.	Camila Peña	Received

1403-PS	IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS	Sheila Pierson	Received

1406-PS	WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA	Cecile Gruchet	Received

1408-PS	PROGNOSTIC SIGNIFICANCE OF CD56 EXPRESSION ON BONE MARROW PLASMA CELLS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.	Giulia Rivoli	Received

1410-PS	DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT.	Romain Gounot	Received

1412-PS	POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA	Cecile Gruchet	Received

1413-PS	INCIDENCE OF NEGATIVE MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT	Carolina Afonso	Received

1415-PS	SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER	Luis Gerardo Rodríguez-Lobato	Received

1421-PS	HONEUR (HEAMATOLOGY OUTCOMES NETWORK IN EUROPE) DISTRIBUTED STATISTICS IN A FEDERATED MODEL TO SUPPORT REAL WORLD DATA RESEARCH IN HEMATOLOGY	Michel Van Speybroeck	Received

1423-PS	NEXT-GENERATION SEQUENCING STUDY OF V(D)J REARRANGEMENTS ON NON-CR PATIENTS SHOWING MRD NEGATIVITY BY NEXT-GENERATION FLOW	Kim Sung-Min	Received

1424-PS	THE CRAB SCORE: A SIMPLE PROGNOSTIC TOOL IN MULTIPLE MYELOMA	Helena Bean	Received

1427-PS	THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA	Linda Little	Received

1432-PS	3-WEEKLY DARATUMUMAB-IMID-DEXAMETHASONE IS HIGHLY EFFICACIOUS, HENCE FINANCIALLY AFFORDABLE WITH ENORMOUS ECONOMIC IMPACT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN LESS AFFLUENT COUNTRIES	Eva Hortas	Received

1435-PS	SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION	Shoichiro Kato	Received

1436-PS	IFN-? TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO.	Harini Nivarthi	Received

1438-PS	DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS	Vibe Skov	Received

1443-PS	BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2/V617F MPN MOUSE MODEL	Peter Mller	Received

1447-PS	ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34 CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS	Paolo Catarsi	Received

1452-PS	GLI-1, EFFECTOR OF CANONICAL HEDGEHOG SIGNALING PATHWAY, DOES NOT SEEM TO BE DYSREGULATED IN PATIENTS WITH MYELOFIBROSIS	Marko Lucijanic	Received

1453-PS	CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS	Jessica Petiti	Received

1457-PS	MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS)	Christoph Klade	Received

1458-PS	RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT	Barbara Mora	Received

1461-PS	FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES	Tanasi Ilaria	Received

1462-PS	SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY	Margherita Maffioli	Received

1466-PS	CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW	Olivia Geen	Received

1470-PS	EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA	Veronika Buxhofer-Ausch	Received

1472-PS	CURRENT PRACTICE IN MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS	Mathieu Wemeau	Received

1474-PS	NON-HODGKIN LYMPHOMA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Kentaro Yoshinaga	Received

1475-PS	COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA	Nanna Broens	Received

1476-PS	APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS	Marian Stevens-Kroef	Received

1481-PS	PLATELET REACTIVITY AND RESPONSE TO ANTIPLATELET DRUGS IN THROMBOCYTOPENIA AND THROMBOCYTOSIS	Lidia Usnarska-Zubkiewicz	Received

1488-PS	ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN THE ECULIZUMAB ERA: PRESENTATION, RESPONSE TO TREATMENT AND EVALUATION OF AN ECULIZUMAB WITHDRAWAL STRATEGY	Lucy Neave	Received

1492-PS	ASSESSING TREATMENT RESPONSE IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AN INNOVATIVE SHEAR FLOW-BASED ASSAY	Chiara Vendramin	Received

1493-PS	NEXT-GENERATION SEQUENCING REVEALS DISTINCT EXPANDED T-CELL RECEPTOR (TCR) B-CHAIN CLONOTYPES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)	Amna Malik	Received

1495-PS	FUNCTIONAL ASSAYS USING WASHED PLATELETS FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: A RETROSPECTIVE STUDY COMPARING HEPARIN- INDUCED PLATELET ACTIVATION TEST VERSUS 14C-SEROTONIN RELEASE ASSAY	Vasiliki GKALEA	Received

1497-PS	NEUTROPHIL EXTRACELLULAR TRAPS (NETS), BLOOD CELL COUNTS AND THROMBOTIC RISK IN ITP PATIENTS	Maria L Lozano	Received

1499-PS	THE EMOTIONAL IMPACT OF WATCH AND WAIT FOR CLL	Lauren Walton	Received

1502-PS	VALIDATION OF HAND GRIP STRENGTH AS A SCREENING TOOL FOR FRAILTY IN OLDER PATIENTS ON TREATMENT FOR HEMATOLOGIC MALIGNANCIES: THE FRAILTY TASK FORCE STUDY	Tommasina Guglielmelli	Received

1504-PS	ASSESSMENT OF HM-PRO ITALIAN VERSION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN CLINICAL PRACTICE	Esther Oliva	Received

1506-PS	APREPITANT AS ADJUNCT FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH HEMATOLOGIC MALIGNANCY UNDERGOING HIGHLY EMETOGENIC CHEMOTHERAPY: A META-ANALYSIS	Feroni Pella Panjaitan	Received

1508-PS	QUALITY OF LIFE AND PERCEPTION OF HEALTH CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE UK	Sophie Wintrich	Received

1509-PS	QoL IN PATIENTS WITH R/R MULTIPLE MYELOMA DURING IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION AND IXAZOMIB MAINTENANCE THERAPY AND COMPARISON TO THE GENERAL POPULATION	Heinz Ludwig	Received

1511-PS	THE FINANCIAL IMPACT OF ACUTE LEUKAEMIA	Lauren Walton	Received

1512-PS	THE DIAGNOSTIC YIELD OF BONE MARROW BIOPSY IN PATIENTS WITH LIVER FAILURE	Thinzar Ko Ko	Received

1515-PS	PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION	Rouslan Kotchetkov	Received

1516-PS	COST-EFFECTIVENESS OF RISK-STRATIFIED TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA	Ayesha Sajjad	Received

1517-PS	MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO-INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DONT BENEFIT FROM CHEMOTHERAPY	VINCENT THIBAUD	Received

1520-PS	INCENTIVE SPIROMETRY TO PREVENT ACUTE CHEST SYNDROME IN ADULTS WITH SICKLE CELL DISEASE; A MULTICENTER RANDOMIZED CLINICAL TRIAL	Charlotte van Tuijn	Received

1524-PS	WHEN IS A CT NEEDED TO DIAGNOSE ACUTE PULMONARY EMBOLISM IN INDIVIDUALS WITH SICKLE CELL DISEASE	Julie Kanter	Received

1530-PS	POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY	Rohtesh Mehta	Received

1534-PS	EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA	Catherine Tang	Received

1535-PS	AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED BY POST-TRANSPLANT IMMUNOTHERAPY WITH NIVOLUMAB AND UNSELECTED AUTOLOGOUS LYMPHOCYTES INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA	Fabio Guolo	Received

1538-PS	SAFETY OF HEMATOPOIETIC STEM CELL DONATION. RETROSPECTIVE ANALYSIS OF EARLY POST DONATION FOLLOW UP IN VOLUNTARY DONORS REGISTERED IN DKMS FOUNDATION DONOR CENTER, POLAND	Tigran Torosian	Received

1541-PS	OUTCOMES OF AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR BPDCN	Muzaffar Qazilbash	Received

1548-PS	SAFETY AND EFFICACY OF CANNABIDIOL FOR SEVERE ACUTE GRAFT VERSUS HOST DISEASE - A PHASE I/II STUDY	Liat Shargian-Alon	Received

1551-PS	INTENSIVE ORAL CARE CAN REDUCE BLOOD STREAM INFECTION POST NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC HSCT	Tatsuya Suwabe	Received

1559-PS	EFFICACY AND TOXICITY OF SEAM (SEMUSTINE, ETOPOSIDE, CYTARABINE, AND MELPHALAN) CONDITIONING REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMA	Eva Hortas	Received

1561-PS	RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS.	Issa Khouri	Received

1563-PS	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VS. ANTITHYMOCYTE GLOBULIN AS GVHD PROPHYLAXIS FOR MISMATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION	Charlotte NYKOLYSZYN	Received

1564-PS	HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH DETECTABLE DISEASE AT TRANSPLANT	Samer Srour	Received

1571-PS	EVALUATION OF RISK FACTORS OF GVHD FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ? THALASSEMIA MAJOR:10 YEARS FOLLOW-UP IN 568 PATIENTS	Wanxia Tan	Received

1576-PS	ADENOSINE DIPHOSPHATE RECEPTOR GENE (P2Y12) SEQUENCE VARIANTS AMONG SWEDISH, PALESTINIAN AND CONGOLESE INDIVIDUALS	Mohammad Asees	Received

1578-PS	EPIDEMIOLOGY AND RISK ASSESSMENT OF PEDIATRIC VENOUS THROMBOEMBOLISM IN KOREA	Jae Min Lee	Received

1581-PS	COMPLEMENT SYSTEM ANALYSES IN PATIENTS SUSPECTED TO HAVE ATYPICAL HEMOLYTIC UREMIC SYNDROME	Jorge Martínez Nieto	Received

1582-PS	DECREASED PLATELET REACTIVITY IS ASSOCIATED WITH AN INFLAMMATORY STATUS IN PATIENTS WITH CANCER	Julia Riedl	Received

1586-PS	EFFECT OF ORAL ANTICOAGULANT TREATMENT ON THE MORTALITY OF PATIENTS WITH ACUTE HEART FAILURE: ANALYSIS BY PROPENSITY SCORE MATCHING.	M ANGELES FERNANDEZ RODRIGUEZ	Received

1587-PS	EDUCATIONAL INTERVENTION ENCOURAGING APPROPRIATE USE OF BLOOD TRANSFUSIONS EXTENDED FOLLOW UP AND COMPARATIVE STUDY	Oren Pasvolsky	Received

1588-PS	FIBRINOLYSIS IN PATIENTS WITH CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND THE EFFECT OF PLATELET TRANSFUSION.	Floor Heubel-Moenen	Received

1592-PS	EFFECT OF ANAEMIA ON MUSCLE OXYGEN SATURATION DURING EXERCISE	Philip Crispin	Received

24th Congress of EHA

June 13-16, 2019 Amsterdam

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 22/06/2019 TO 22/06/2019

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.24EHA.2019



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access